Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1/programmed death ligand 1 (PD1/PDL1) have been used with great success in several cancers and are now widely accepted as one of the standard therapies in cancer treatment [11]. This evidence concerns the gene CD274 and cancer.